Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022
June 08, 2022 07:00 ET
|
Amryt Pharma plc
Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022 DUBLIN, Ireland, and Boston MA, June 8, 2022 Amryt (Nasdaq: AMYT), a...
Posting of Annual Report and Notice of AGM
June 01, 2022 07:00 ET
|
Amryt Pharma plc
Posting of Annual Report and Notice of AGM DUBLIN, Ireland, and Boston MA, June 1, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing...
Amryt Announces Details of EMA Contingent Value Rights Payment
May 17, 2022 07:00 ET
|
Amryt Pharma plc
Amryt Announces Details of EMA Contingent Value Rights Payment DUBLIN, Ireland, and Boston MA, May 17, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to...
Amryt Announces New Patent for Mycapssa®
May 11, 2022 07:00 ET
|
Amryt Pharma plc
Amryt Announces New Patent for Mycapssa® DUBLIN, Ireland, and Boston MA, May 11, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and...
Amryt Reports Record Q1 2022 Results
May 04, 2022 07:00 ET
|
Amryt Pharma plc
Amryt Reports Record Q1 2022 Results CHMP adopts positive opinion for Filsuvez® for the treatment of Dystrophic and Junctional EB Reaffirming FY 2022 revenue guidance to $260M - $270M, representing...
CHMP adopts positive opinion for Filsuvez® for the treatment of Dystrophic and Junctional EB
April 22, 2022 10:15 ET
|
Amryt Pharma plc
CHMP adopts positive opinion for Filsuvez® for the treatment of Dystrophic and Junctional EB Positive opinion based on largest ever pivotal global Phase 3 EASE study undertaken in EB ...
Amryt to Report Q1 2022 Results on May 4, 2022
April 14, 2022 07:00 ET
|
Amryt Pharma plc
Amryt to Report Q1 2022 Results on May 4, 2022 DUBLIN, Ireland, and Boston MA, April 14, 2022, Amryt (Nasdaq: AMYT) a global, commercial-stage biopharmaceutical company dedicated to acquiring,...
Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa® (oral octreotide) from the 2nd Year of OPTIMAL Open Label Extension Study in Acromegaly Patients
April 13, 2022 07:00 ET
|
Amryt Pharma plc
Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa® (oral octreotide) from the 2nd Year of OPTIMAL Open Label Extension Study in Acromegaly Patients Acromegaly patients...
Amryt Supports World Lipodystrophy Day - March 31, 2022
March 31, 2022 07:00 ET
|
Amryt Pharma plc
Amryt Supports World Lipodystrophy Day - March 31, 2022 DUBLIN, Ireland, and Boston MA, March 31, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on...
Amryt Announces Positive Interim Analysis Data From Open Label Phase of EASE Phase 3 Trial in EB
March 26, 2022 11:00 ET
|
Amryt Pharma plc
Amryt Announces Positive Interim Analysis Data From Open Label Phase of EASE Phase 3 Trial in EB Late-breaking oral presentation at the American Academy of Dermatology Annual meeting 2022 ...